Clinical trial · Observational
Tolerance of Anti-Cancer Therapy in the Elderly
NCT05251922CI-TRIAL-00056675TOASTIEunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multicentre observational study evaluating frailty and tolerance of chemotherapy in the elderly.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapeutic Toxicity | — | UNRESOLVED | — |
| Frailty | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To validate the CARG scoring system
- timeFrame
- 6 months follow up
- description
- To validate the CARG scoring system (a score which is calculated by the doctor using patient information) in a UK real-world population and show feasibility of implementing CARG scoring in routine NHS practice. The investigators will collect the information required and calculate a CARG score for each participant. The investigators will record Grade 3-5 chemotherapy toxicities (as assessed using CTCAEv5) for each participant. The investigators will evaluate if the CARG score is predictive of Grade 3-5 toxicity (as assessed using CTCAEv5) in this UK real-world population. The investigators will record how long it takes to collect this information and calculate the score to see if it is feasible to implement this in a real world setting.
Secondary outcomes (10)
- measure
- Describe frailty in elderly patients (>65years) in the UK NHS prior to starting chemotherapy - demographics
- timeFrame
- 6 months follow up
- description
- The investigators are reporting demographics: age (years) and gender
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Age \>65years * About to start first line chemotherapy for a solid tumour based malignancy * Chemotherapy given for any intent eg. adjuvant or palliative * Estimated survival of \>3months * Able to comprehend and complete questionnaire. Exclusion Criteria: * Medical or psychiatric condition impairing ability to consent * Participant is enrolled in another clinical trial * Prior chemotherapy for any indication * Receiving concurrent radiotherapy (RT) or immunotherapy (IT) * Unable to provide informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.